英夫利西单抗与炎症性肠病患者长期普遍体重增加无关:一项全国性研究
基于丹麦全国健康登记数据的观察性研究纳入851例启动英夫利西单抗治疗的克罗恩病(CD)和溃疡性结肠炎(UC)患者,随访诱导期(0-90天)和维持期(91-270天)体重变化。多数患者维持期未观察到长期体重增加;女性CD且起始治疗时体重不足者平均增重7.5 kg;CD和UC的男女性体重正常或增加者维持期平均增重<2 kg;体重不足的CD和UC男性诱导期分别增重2.9 kg(95%CI 2.1-3.6)和2.9 kg(95%CI 1.9-3.9),维持期均无统计学显著增重;不足3%的患者体重增加超过基线体重的10%。作者认为抗TNF-α治疗患者的体重增加不太可能由抗TNF-α治疗效应所致。
要点
- 多数CD和UC患者维持期未出现长期体重增加。
- 女性CD且起始治疗时体重不足者平均增重7.5 kg。
- CD和UC的男女性体重正常或增加者维持期平均增重<2 kg。
核心结论
- 接受抗TNF-α治疗患者的体重增加不太可能由抗TNF-α治疗效应所致。
研究设计与样本
- 基于丹麦全国健康登记数据的全国性观察性研究,纳入851例启动英夫利西单抗治疗的CD和UC患者,随访诱导期(0-90天)和维持期(91-270天)体重变化,采用多水平混合效应线性回归模型分析英夫利西单抗使用与体重增加的关联。
主要发现
- 851例启动英夫利西单抗治疗的CD和UC患者中,多数患者维持期未观察到长期体重增加。
- 女性CD且起始治疗时体重不足者平均增重7.5 kg。
- CD和UC的男女性体重正常或增加者维持期平均增重<2 kg。
- 体重不足的CD男性诱导期增重2.9 kg(95%CI 2.1-3.6),维持期无统计学显著增重。
- 体重不足的UC男性诱导期增重2.9 kg(95%CI 1.9-3.9),维持期无统计学显著增重;研究期间不足3%的患者体重增加超过基线体重的10%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with Crohn's disease (CD) and ulcerative colitis (UC) may lose weight during periods of active disease and may gain weight when inflammation heals. Studies have hypothesized an association between antitumor necrosis factor-alpha (anti-TNF-α) and unintended weight gain during maintenance therapy, and this association has not been previously clarified. METHODS: In a nationwide observational study based on Danish national health registries, we included patients who initiated therapy with infliximab and followed changes in weight during induction therapy (0-90 days) and maintenance therapy (91-270 days). The association between the use of infliximab and weight gain was analyzed by a multilevel mixed-effects linear regression model. RESULTS: Among 851 patients with CD and UC who initiated infliximab therapy, long-term weight gain was not observed during maintenance therapy in most of the patients. Women with CD who were underweight at the initiation of therapy had an average weight gain of 7.5 kg. Men and women with CD and UC with normal or increased body mass index had an average weight gain of <2 kg during maintenance therapy. Underweight men with CD and UC gained 2.9 kg (95% confidence interval 2.1-3.6) and 2.9 kg (95% confidence interval 1.9-3.9), respectively, in the first 90 days, although neither group had statistically significant weight gain in the maintenance period. Less than 3% of the patients had weight gain greater than 10% of their baseline body weight during the study period. DISCUSSION: Weight gain among patients treated with anti-TNF-α therapies is unlikely to be due to an effect from anti-TNF-α therapy.
引用
- Winter RW, Friedman S, Nielsen J, et al. Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease: A Nationwide Study. Am J Gastroenterol. 2022. PMID: 35287136. doi:10.14309/ajg.0000000000001721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。